Apyx Medical (NASDAQ:APYX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “Apyx Medical Corporation is an energy technology company. It provides products in the cosmetic and surgical markets. The company’s Helium Plasma Technology is marketed and sold as Renuvion(R) in the cosmetic surgery market and J-Plasma(R) in the hospital surgical market. Apyx Medical Corporation, formerly known as Bovie Medical Corporation, is based in FL, United States. “

A number of other equities analysts have also weighed in on the stock. Colliers Securities restated a “buy” rating on shares of Apyx Medical in a report on Tuesday, March 30th. Piper Sandler upped their price target on Apyx Medical from $8.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, January 29th.

Shares of NASDAQ:APYX opened at $9.02 on Tuesday. Apyx Medical has a 12-month low of $2.81 and a 12-month high of $12.01. The stock has a market capitalization of $309.55 million, a price-to-earnings ratio of -19.19 and a beta of 0.72. The stock has a fifty day simple moving average of $10.45 and a two-hundred day simple moving average of $8.09. The company has a current ratio of 7.05, a quick ratio of 6.49 and a debt-to-equity ratio of 0.01.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings results on Tuesday, March 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.07. Apyx Medical had a negative net margin of 64.16% and a negative return on equity of 24.21%. As a group, equities research analysts predict that Apyx Medical will post -0.42 EPS for the current year.

Large investors have recently bought and sold shares of the business. Kestra Advisory Services LLC purchased a new position in shares of Apyx Medical in the 4th quarter worth $1,611,000. Millrace Asset Group Inc. grew its holdings in Apyx Medical by 208.7% during the fourth quarter. Millrace Asset Group Inc. now owns 166,536 shares of the company’s stock valued at $1,199,000 after purchasing an additional 112,594 shares during the period. BlackRock Inc. increased its holdings in Apyx Medical by 4.3% in the 4th quarter. BlackRock Inc. now owns 2,328,764 shares of the company’s stock worth $16,767,000 after acquiring an additional 96,536 shares in the last quarter. Calamos Advisors LLC purchased a new stake in shares of Apyx Medical in the fourth quarter worth $535,000. Finally, Wolff Wiese Magana LLC bought a new stake in shares of Apyx Medical during the 4th quarter valued at $471,000. 52.00% of the stock is owned by institutional investors and hedge funds.

About Apyx Medical

Apyx Medical Corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.

Read More: What is a SEC Filing?

Get a free copy of the Zacks research report on Apyx Medical (APYX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.